LOS ANGELES, United States: The research report published by QYResearch gives the potential headway openings that prevails in the global market. Market study of the global Animal Stem Cell Therapy market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Animal Stem Cell Therapy industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Animal Stem Cell Therapy production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Animal Stem Cell Therapy market include _ Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1427718/global-animal-stem-cell-therapy-market

Segmental Analysis

The report has classified the global Animal Stem Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Animal Stem Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Animal Stem Cell Therapy industry.

Global Animal Stem Cell Therapy Market Segment By Type:

, Dogs, Horses, Others

Global Animal Stem Cell Therapy Market Segment By Application:

, Veterinary Hospitals, Research Organizations Key Players: The Key manufacturers that are operating in the

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Animal Stem Cell Therapy industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Animal Stem Cell Therapy market include _ Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Key questions answered in the report:

Enquire Customization in The Report: https://www.qyresearch.com/customize-request/form/1427718/global-animal-stem-cell-therapy-market

TOC

Table of Contents 1 Animal Stem Cell Therapy Market Overview1.1 Product Overview and Scope of Animal Stem Cell Therapy1.2 Animal Stem Cell Therapy Segment by Type1.2.1 Global Animal Stem Cell Therapy Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Dogs1.2.3 Horses1.2.4 Others1.3 Animal Stem Cell Therapy Segment by Application1.3.1 Animal Stem Cell Therapy Sales Comparison by Application: 2020 VS 20261.3.2 Veterinary Hospitals1.3.3 Research Organizations1.4 Global Animal Stem Cell Therapy Market Size Estimates and Forecasts1.4.1 Global Animal Stem Cell Therapy Revenue 2015-20261.4.2 Global Animal Stem Cell Therapy Sales 2015-20261.4.3 Animal Stem Cell Therapy Market Size by Region: 2020 Versus 2026 2 Global Animal Stem Cell Therapy Market Competition by Manufacturers2.1 Global Animal Stem Cell Therapy Sales Market Share by Manufacturers (2015-2020)2.2 Global Animal Stem Cell Therapy Revenue Share by Manufacturers (2015-2020)2.3 Global Animal Stem Cell Therapy Average Price by Manufacturers (2015-2020)2.4 Manufacturers Animal Stem Cell Therapy Manufacturing Sites, Area Served, Product Type2.5 Animal Stem Cell Therapy Market Competitive Situation and Trends2.5.1 Animal Stem Cell Therapy Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Animal Stem Cell Therapy Players (Opinion Leaders) 3 Animal Stem Cell Therapy Retrospective Market Scenario by Region3.1 Global Animal Stem Cell Therapy Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Animal Stem Cell Therapy Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Animal Stem Cell Therapy Market Facts & Figures by Country3.3.1 North America Animal Stem Cell Therapy Sales by Country3.3.2 North America Animal Stem Cell Therapy Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Animal Stem Cell Therapy Market Facts & Figures by Country3.4.1 Europe Animal Stem Cell Therapy Sales by Country3.4.2 Europe Animal Stem Cell Therapy Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Animal Stem Cell Therapy Market Facts & Figures by Region3.5.1 Asia Pacific Animal Stem Cell Therapy Sales by Region3.5.2 Asia Pacific Animal Stem Cell Therapy Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Animal Stem Cell Therapy Market Facts & Figures by Country3.6.1 Latin America Animal Stem Cell Therapy Sales by Country3.6.2 Latin America Animal Stem Cell Therapy Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Animal Stem Cell Therapy Market Facts & Figures by Country3.7.1 Middle East and Africa Animal Stem Cell Therapy Sales by Country3.7.2 Middle East and Africa Animal Stem Cell Therapy Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Animal Stem Cell Therapy Historic Market Analysis by Type4.1 Global Animal Stem Cell Therapy Sales Market Share by Type (2015-2020)4.2 Global Animal Stem Cell Therapy Revenue Market Share by Type (2015-2020)4.3 Global Animal Stem Cell Therapy Price Market Share by Type (2015-2020)4.4 Global Animal Stem Cell Therapy Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Animal Stem Cell Therapy Historic Market Analysis by Application5.1 Global Animal Stem Cell Therapy Sales Market Share by Application (2015-2020)5.2 Global Animal Stem Cell Therapy Revenue Market Share by Application (2015-2020)5.3 Global Animal Stem Cell Therapy Price by Application (2015-2020) 6 Company Profiles and Key Figures in Animal Stem Cell Therapy Business6.1 Medivet Biologics LLC6.1.1 Corporation Information6.1.2 Medivet Biologics LLC Description, Business Overview and Total Revenue6.1.3 Medivet Biologics LLC Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.1.4 Medivet Biologics LLC Products Offered6.1.5 Medivet Biologics LLC Recent Development6.2 VETSTEM BIOPHARMA6.2.1 VETSTEM BIOPHARMA Animal Stem Cell Therapy Production Sites and Area Served6.2.2 VETSTEM BIOPHARMA Description, Business Overview and Total Revenue6.2.3 VETSTEM BIOPHARMA Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.2.4 VETSTEM BIOPHARMA Products Offered6.2.5 VETSTEM BIOPHARMA Recent Development6.3 J-ARM6.3.1 J-ARM Animal Stem Cell Therapy Production Sites and Area Served6.3.2 J-ARM Description, Business Overview and Total Revenue6.3.3 J-ARM Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.3.4 J-ARM Products Offered6.3.5 J-ARM Recent Development6.4 U.S. Stem Cell, Inc6.4.1 U.S. Stem Cell, Inc Animal Stem Cell Therapy Production Sites and Area Served6.4.2 U.S. Stem Cell, Inc Description, Business Overview and Total Revenue6.4.3 U.S. Stem Cell, Inc Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.4.4 U.S. Stem Cell, Inc Products Offered6.4.5 U.S. Stem Cell, Inc Recent Development6.5 VetCell Therapeutics6.5.1 VetCell Therapeutics Animal Stem Cell Therapy Production Sites and Area Served6.5.2 VetCell Therapeutics Description, Business Overview and Total Revenue6.5.3 VetCell Therapeutics Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.5.4 VetCell Therapeutics Products Offered6.5.5 VetCell Therapeutics Recent Development6.6 Celavet Inc.6.6.1 Celavet Inc. Animal Stem Cell Therapy Production Sites and Area Served6.6.2 Celavet Inc. Description, Business Overview and Total Revenue6.6.3 Celavet Inc. Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.6.4 Celavet Inc. Products Offered6.6.5 Celavet Inc. Recent Development6.7 Magellan Stem Cells6.6.1 Magellan Stem Cells Animal Stem Cell Therapy Production Sites and Area Served6.6.2 Magellan Stem Cells Description, Business Overview and Total Revenue6.6.3 Magellan Stem Cells Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.4.4 Magellan Stem Cells Products Offered6.7.5 Magellan Stem Cells Recent Development6.8 Kintaro Cells Power6.8.1 Kintaro Cells Power Animal Stem Cell Therapy Production Sites and Area Served6.8.2 Kintaro Cells Power Description, Business Overview and Total Revenue6.8.3 Kintaro Cells Power Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.8.4 Kintaro Cells Power Products Offered6.8.5 Kintaro Cells Power Recent Development6.9 Animal Stem Care6.9.1 Animal Stem Care Animal Stem Cell Therapy Production Sites and Area Served6.9.2 Animal Stem Care Description, Business Overview and Total Revenue6.9.3 Animal Stem Care Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.9.4 Animal Stem Care Products Offered6.9.5 Animal Stem Care Recent Development6.10 Animal Cell Therapies6.10.1 Animal Cell Therapies Animal Stem Cell Therapy Production Sites and Area Served6.10.2 Animal Cell Therapies Description, Business Overview and Total Revenue6.10.3 Animal Cell Therapies Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.10.4 Animal Cell Therapies Products Offered6.10.5 Animal Cell Therapies Recent Development6.11 Cell Therapy Sciences6.11.1 Cell Therapy Sciences Animal Stem Cell Therapy Production Sites and Area Served6.11.2 Cell Therapy Sciences Animal Stem Cell Therapy Description, Business Overview and Total Revenue6.11.3 Cell Therapy Sciences Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.11.4 Cell Therapy Sciences Products Offered6.11.5 Cell Therapy Sciences Recent Development6.12 Animacel6.12.1 Animacel Animal Stem Cell Therapy Production Sites and Area Served6.12.2 Animacel Animal Stem Cell Therapy Description, Business Overview and Total Revenue6.12.3 Animacel Animal Stem Cell Therapy Sales, Revenue and Gross Margin (2015-2020)6.12.4 Animacel Products Offered6.12.5 Animacel Recent Development 7 Animal Stem Cell Therapy Manufacturing Cost Analysis7.1 Animal Stem Cell Therapy Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Animal Stem Cell Therapy7.4 Animal Stem Cell Therapy Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Animal Stem Cell Therapy Distributors List8.3 Animal Stem Cell Therapy Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Animal Stem Cell Therapy Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Animal Stem Cell Therapy by Type (2021-2026)10.1.2 Global Forecasted Revenue of Animal Stem Cell Therapy by Type (2021-2026)10.2 Animal Stem Cell Therapy Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Animal Stem Cell Therapy by Application (2021-2026)10.2.2 Global Forecasted Revenue of Animal Stem Cell Therapy by Application (2021-2026)10.3 Animal Stem Cell Therapy Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Animal Stem Cell Therapy by Region (2021-2026)10.3.2 Global Forecasted Revenue of Animal Stem Cell Therapy by Region (2021-2026)10.4 North America Animal Stem Cell Therapy Estimates and Projections (2021-2026)10.5 Europe Animal Stem Cell Therapy Estimates and Projections (2021-2026)10.6 Asia Pacific Animal Stem Cell Therapy Estimates and Projections (2021-2026)10.7 Latin America Animal Stem Cell Therapy Estimates and Projections (2021-2026)10.8 Middle East and Africa Animal Stem Cell Therapy Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the article here:

New Trend: Animal Stem Cell Therapy Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 | Medivet Biologics LLC, VETSTEM...

The international Society for Stem Cell Application ISSCA and Medicel Chile have announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2020.

The program will include Seven days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Medicels Chief Scientific Officer and Other leading Scientists will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.

Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting

The graduate course will be scheduled 3 times during 2020 starting February 23rd

Our end goal in Launching this Fellowship program is to help physicians that are looking for really advanced and formal training in Cellular Therapies and Regenerative Medicine We want to provide them the necessary skills and in depth specialization that is lacking in our smaller point of care programs , noted Benito Novas ISSCA Public Relations Director

To learn more about the February 2020 certification event in Santiago, or any of the other upcoming certification courses around the world, visit the ISSCA website. http://www.issca.us

About the International Society for Stem Cells Applications (ISSCA)

The International Society for Stem Cells Applications (ISSCA) is a multidisciplinarycommunity of scientists and physicians, all of whom aspire to treat diseases and lessenhuman suffering through advances in science, technology, and the practice of regenerativemedicine. Incorporated and Trademarked in the United States of America as a non-profit entity, ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.Their code of ethics emphasizes principles of morals and ethical conducts.

ISSCAs vision is to take a leadership position in promoting excellence and settingstandards in the regenerative medicine fields of publication, research, education, training,and certification. ISSCA serves its members through advancements made to the specialtyof regenerative medicine. They aim to encourage more physicians to practice regenerativemedicine and make it available to benefit patients both nationally and globally.

For more information, please visit the ISSCAs website or send an email toinfo@stemcellsgroup.com

About Medicel Chile

Medicel Chile is one of the premiere regenerative medicine treatment centers in the country of Chile, conveniently located in Santiago de Chile, one of the largest metropolitan areas in Latin America. Medicel carries with it a reputation as one of the most scientifically advanced and professional regenerative medicine Laboratories in Chile, and this is in no small part due to its highly-qualified team of scientists and medical professionals and advisers, who research tirelessly to head new breakthroughs in the fields of cellular therapy and cryopreservation, which is the freezing of a stem cell sample to ensure its longevity and freshness, should the patient receiving the service ever wish to use their frozen cells for some future malady.

About International Society for Stem Cells Applications

The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.

At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerativemedicine and make it available to benefit patients both nationally and globally.

For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com

Excerpt from:

International Society for Stem Cell Application ISSCA to Launch Postgraduate Studies Program in Stem Cell Therapies and Regenerative Medicine in...

"Global Stem Cell Therapy Market Assessment Report: Present & Forecast Evaluation"is a comprehensive blend of qualitative and quantitative analysis in terms of Stem Cell Therapy market size, demand, revenue, gross margin, value, and volume. The whole research study is segmented based on regions, product type, application, and top companies operating in Stem Cell Therapy Market. The report begins with the introduction on Stem Cell Therapy Industry, drivers, restraints, trends, PEST analysis, PORTERs Five Forces analysis. The macro-economic factors, Stem Cell Therapy manufacturing cost, industry chain structure and pricing analysis are conducted. The pandemic impact in terms of production, demand, profit, growth scope is covered in our latest report updated in June 2020.

Browse More Details Or Receive Free Sample Copy With Graphs & Charts: https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

The Stem Cell Therapy production, market performance over past and present years, opportunity mapping, investment feasibility and growth orbits are specified in this research report. The regional markets share of every industry player, product type and application is studied which is as follows:

Top Companies Involved in Stem Cell Therapy Industry are:Osiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCRPharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Top Product Types Evaluated are:AutologousAllogeneic

Top Applications studied are:Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

To derive the vital Stem Cell Therapy Industry aspects like market share, revenue, production, demand various primary interviews and interactions are carried out with industry experts like VPs, CEOs, Marketing Managers, R&D Managers, distributors, national sales mangers of top companies. Primary and performance analysis is carried out by interviewing the distributors, traders, dealers and more. The most crucial segment like Stem Cell Therapy Market competition and trends is studied in this report.

Ask Any Query, Request Custom Information or View Report TOC: https://www.reportscheck.com/shop/2021-2026-report-on-global-stem-cell-therapy-market-by-player-region-type-application-and-sales-channel/

The report evaluates the positive and negative impact of ongoing situations on Stem Cell Therapy Industry with forecast opportunities and CAGR value. The historical and present industry situations, market trends, technological innovations, regulations, upcoming technologies, and challenges are covered. The Stem Cell Therapy Market revenue is expected to surpass US$ XX Million by 2021 with a growth rate of xx.xx% from 2021-2027.

Regional Perspective and Stem Cell Therapy Analysis:

The market scope and regional division include North America, Europe, Asia-Pacific, Middle East & Africa, South America, and Rest of the World. The industry presence in the Asia-Pacific region is expected to expand at a good pace due to the increase in production facilities, existing players developing new opportunities and new players emerging in Stem Cell Therapy Market. North America is expected to reach a higher market share followed by the European region. Demand for Stem Cell Therapy products and its relevant applications across different market segments is growing rapidly.

Stem Cell Therapy Market Analysis Based on Top Companies:

After the market competition and overview by top players, company profiles of every Stem Cell Therapy Industry player is provided in detail. This segment covers the company overview, business portfolio, production details & description, vital financials, developments, SWOT analysis, and more. Top companies across the globe are profiled in this research study. The report can be customized based on the users choice and more players can be added as per requirements.

The forecast Stem Cell Therapy industry vision covers the market size estimation, growth driving factors, risk analysis & mitigation, new entrants SWOT analysis, and investment feasibility.

Key Assessments & Stem Cell Therapy Market Research Report Highlights:

Thanks for reading our article. For any queries, questions, or custom requirements feel free to reach us or contact our analyst. We offer the report as per the clients stated scenario.

Contact Us:

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

Original post:

Tag: Stem Cell Therapy Growth - Cole of Duty

This article was originally published here

Stem Cell Res Ther. 2020 Jul 16;11(1):291. doi: 10.1186/s13287-020-01802-8.

ABSTRACT

Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.

PMID:32678017 | DOI:10.1186/s13287-020-01802-8

Visit link:

A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report -...

Global Stem Cell Banking Market Report Industry Analysis, Market Size, Historical-Current-Future Trends, Competitive Landscape and Forecasts to 2026

The markets growth and development depends on the factors such as the modernization and the current technological advancements. This research study on the Stem Cell Banking market has considered all these aspects and the information provided is based on the current market trends. TheStem Cell Banking marketreport includes all the minute and important information about the Stem Cell Banking market which aids the clients to rethink on their current market strategies and implement new ones as per the market standards. The major data points that are mentioned in the Stem Cell Banking report includes the growth factors, limitations of the market, future market opportunities, market challenges, and others. All these facts about the market are explained in detail so as to the client understands the market condition easily.

Get FREE Sample PDF of This Research Report::https://www.marketdataanalytics.biz/global-stem-cell-banking-market-report-2020-industry-analysis-16121.html#request-sample

The major market players that are operating in the Stem Cell Banking market areCCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech. The market has been segmented based onUmbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other. The market segmentation is not only restricted toDiseases Therapy, Healthcarebut also includes the sub segments which also contributes to the market growth and development. The geographical prominence of the Stem Cell Banking market is categorized into Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. Again the market data is not restricted to regional presence but every prominent country-wise data is also included for understanding the Stem Cell Banking market in-depth.

Certain conditions that were considered while making Stem Cell Banking market data analysis include the current market situation, if any kind of restrictions were imposed by any of the regulatory bodies that would have impacted the market growth or development in any kind, the investments that are being made for the market development, for instance, the research and development activities, among others. This extensive data on the Stem Cell Banking market will prove constructive for all the existing industry players and the new market entrants to improve their decision-making skills to improve their position in the global Stem Cell Banking market.

View Detailed Report at Link:https://www.marketdataanalytics.biz/global-stem-cell-banking-market-report-2020-industry-analysis-16121.html

Significant aspects of the Reports and Main Highlights:

A detailed look at the Stem Cell Banking Industry Changing business trends in the global Stem Cell Banking market Detailed market bifurcation analysis at different level such as type, application, end user, Regions / countries Historical and forecast size of the Stem Cell Banking market in terms of Revenue (USD Million) Recent industry development and market trends Competitive Landscape and player positioning analysis for the Stem Cell Banking market Key Product Offerings by Major players and business strategies adopted Niche and Potential segments (ex. types, applications, and regions/countries) anticipated to observed promising growth Key challenges faced by operating players in the market space Analysis of major risks associated with the market operations

If Any Inquiry of Stem Cell Banking Report@https://www.marketdataanalytics.biz/global-stem-cell-banking-market-report-2020-industry-analysis-16121.html#inquiry-for-buying

See the article here:

Global Stem Cell Banking Market 2020 Coronavirus (COVID-19) Updated Analysis By Product (Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult...

A new research report published by Fior Markets with the titleBiologics Safety Testing Market by Product Type (Instruments, Services, Kit and Reagents), Test Type (Bioburden tests, Endotoxin, Sterility, Cell Line Authentication, Adventitious Agent Detection Tests, Residual Host Contamination Detection Tests, Characterization Tests and other), Application ( Vaccine Development, Blood Products, Tissue and Tissue related Products testing, Cellular and Gene Therapy and Stem Cell Research), Region, Global Forecast 2020-2027.

Theglobal biologics safety testing marketis expected to grow from USD 3.08 billion in 2019 to USD 7.62 billion by 2027, at a CAGR of 12.2% during the forecast period 2020-2027. Asia-Pacific is expected to increase at the highest CAGR. The rise is healthcare spending, and increasing awareness among the people has anticipated the market growth of the biologics safety testing market. Although, currently North America holds the largest market share as high investments in biotechnology and cancer research has increased the demand for the products. Also, development of vaccines, & drugs and increasing number of R&D investments by many companies has contributed to the market demand. Additionally, increasing number of chronic diseases is anticipated to increase the usage of advanced technologies accelerated the market growth.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/418372/request-sample

Key players in the biologics safety testing market are Toxikon Corporation, Thermo Fisher Scientific Inc., Pace Analytical, Lonza Group, MilliporeSigma, Sartorius Stedim BioOutcome Limited, SGS SA, Merck KFaA, Cytovance Biologics Inc., WuXi Apptec, Charles River Laboratries and others. The companies have been tying up with the research centres in order to adopt the technical advancements and increase the sales margin.

The product type segment includes instruments, services, kit and reagents.Reagents constitutes for the largest market share among all. They can be classified into antibiotics, biological buffers, attachments & matrix factors, etc. The reason for their large market share is the rapid technical advancements and modifications. The test type segment includes bioburden tests, endotoxin, sterility, cell line authentication, adventitious agent detection tests, residual host contamination detection tests, characterization tests and other. Endotoxin dominates the market demand out of all the segments. The rise in use of these tests in sectors such as manufacturing and production of drugs has been the contributing factors. The application segment includes vaccine development, blood products, tissue and tissue related products testing, cellular and gene therapy and stem cell research. Vaccine constitutes of the largest market share as of now in the application segment as because vaccines are made necessary by almost every state. The growing vulnerability to possess disease has increased the use of vaccines over the years which have accelerated the market demand of the biologics safety testing market.

Biologics safety testing prevents bacterial contamination. The products contain serum and blood. The objective of the biologics safety testing devices is to ensure safety of vaccines and biopharmaceuticals by eliminating any bacterial presence. The growing advancement in healthcare sector and continuous innovations in the product have increased the market demand of the product. Also, growing awareness for hygiene among people is the reason why its application has increase over the years.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/biologics-safety-testing-market-by-product-type-instruments-418372.html

About the report:The globalbiologics safety testing market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact UsMark StonePhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

More here:

Global Biologics Safety Testing Market is expected to grow at a CAGR of 12.2% during the forecast pe - PharmiWeb.com

Vertex has long been known for its cystic fibrosis brand, including fast-growing triple-combo med Trikafta. But Vertex has its eyes on much more than cystic fibrosis with a bustling cell and gene therapy pipeline, and now the company's found the manufacturing chief to help it get there.

Vertex has tapped Bristol Myers Squibb veteran E. Morrey Atkinson, Ph.D., as its senior vice president and head of commercial manufacturing and supply chain to help take the drugmaker into its next phase.

Atkinson is the first major C-suite hire under new CEO Reshma Kewalramani, who took the helm earlier this year after switching from the chief medical officer role. His hiring will add an experienced hand in cell and gene therapy manufacturing as Kewalramani steers Vertex's growing and diversified pipeline to the commercial stage.

Until June, Atkinson was senior vice president of global manufacturing operations at Bristol and helped lead the manufacturing integration team for Bristol's $74 billion Celgene merger that closed in November.

In his previous roles at Eli Lilly and Cook Pharmica (now Catalent), Atkinson specialized in biologics manufacturing and led clinical production for some of the earliest viral vectors used in cell and gene therapies. Atkinson also spearheaded the building and qualification of commercial production facilities in the U.S. and Ireland, Vertex said.

RELATED: Vertex plans major Boston expansion to support gene, cell therapy ambitions

In June 2019, Vertex unveiled its plan to build a new cell and gene therapies research site in Boston after putting down $420 million to acquire ExonicsTherapeutics and expand its existing partnership with CRISPR Therapeutics for multiple Duchenne muscular dystrophy candidates.

Vertex followed that investment up with its $950 million buy of Semma Therapeutics in September, adding the biotech's stem-cell-based diabetes treatments into the mix.

In November, Vertex was reportedly in advanced talks to lease a 256,000-square-foot facility in Boston's Innovation Square to house the drugmaker's planned cell and gene therapy unit. Vertex reportedly scoured the greater Boston region for a new foothold, including sites in Cambridge, Waltham and Watertown, but picked Innovation Square because its one of the most advanced projects in the neighborhood, on track to open in 2021.

So far, Vertex hasn't publicly announced the future home for its advanced therapies unit, though. The drugmaker is also runninginvestigational candidates in APOL1-mediated kidney disease, beta thalassemia, sickle disease and alpha-1 antitrypsin deficiency through clinical testing.

RELATED: Vertex CEO Leiden touts gangbusters Trikafta launch in 'mic drop' earnings call

In the meantime, Vertex currently houses its entire continuous manufacturing center for its cystic fibrosis portfolio at a south Boston facility that employs 100, the drugmaker said.

That site has been running at full speed with sales for Vertex's latest CF launch, Trikafta, blowing past analyst consensus on its way to blockbuster status.

In the first quarter, Trikafta hit $895 million in sales after just five months on the market. Those sales are higher than Vertex's three established CF meds combined and put the drug well on track to hit SVB Leerink analyst Geoffrey Porges' prediction of $4.6 billion in annual sales by 2023 and $6.6 billion in 2025.

Trikafta's gangbusters launch came as a fitting sendoff for CEO Jeffrey Leiden, who moved over into the chairman role in favor of then-CMO Kewalramani.

Read the original post:

Vertex hires BMS vet Atkinson to shore up manufacturing for bustling cell and gene therapy pipeline - FiercePharma

LOS ANGELES, United States: QY Research has recently published a report, titled Global Cancer Stem Cell Therapy Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Cancer Stem Cell Therapy market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Cancer Stem Cell Therapy market include: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1528706/global-cancer-stem-cell-therapy-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Cancer Stem Cell Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Cancer Stem Cell Therapy Market Segment By Type:

Autologous Stem Cell TransplantsAllogeneic Stem Cell TransplantsSyngeneic Stem Cell TransplantsOther Cancer Stem Cell Therapy

Global Cancer Stem Cell Therapy Market Segment By Application:

HospitalClinicMedical Research InstitutionOther

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Cancer Stem Cell Therapy market.

Key companies operating in the global Cancer Stem Cell Therapy market include AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1528706/global-cancer-stem-cell-therapy-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Cancer Stem Cell Therapy Revenue1.4 Market by Type1.4.1 Global Cancer Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 20261.4.2 Autologous Stem Cell Transplants1.4.3 Allogeneic Stem Cell Transplants1.4.4 Syngeneic Stem Cell Transplants1.4.5 Other1.5 Market by Application1.5.1 Global Cancer Stem Cell Therapy Market Share by Application: 2020 VS 20261.5.2 Hospital1.5.3 Clinic1.5.4 Medical Research Institution1.5.5 Other1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Cancer Stem Cell Therapy Market Perspective (2015-2026)2.2 Global Cancer Stem Cell Therapy Growth Trends by Regions2.2.1 Cancer Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Cancer Stem Cell Therapy Historic Market Share by Regions (2015-2020)2.2.3 Cancer Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Cancer Stem Cell Therapy Market Growth Strategy2.3.6 Primary Interviews with Key Cancer Stem Cell Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Cancer Stem Cell Therapy Players by Market Size3.1.1 Global Top Cancer Stem Cell Therapy Players by Revenue (2015-2020)3.1.2 Global Cancer Stem Cell Therapy Revenue Market Share by Players (2015-2020)3.1.3 Global Cancer Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Cancer Stem Cell Therapy Market Concentration Ratio3.2.1 Global Cancer Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Cancer Stem Cell Therapy Revenue in 20193.3 Cancer Stem Cell Therapy Key Players Head office and Area Served3.4 Key Players Cancer Stem Cell Therapy Product Solution and Service3.5 Date of Enter into Cancer Stem Cell Therapy Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Cancer Stem Cell Therapy Historic Market Size by Type (2015-2020)4.2 Global Cancer Stem Cell Therapy Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Cancer Stem Cell Therapy Market Size by Application (2015-2020)5.2 Global Cancer Stem Cell Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Cancer Stem Cell Therapy Market Size (2015-2020)6.2 Cancer Stem Cell Therapy Key Players in North America (2019-2020)6.3 North America Cancer Stem Cell Therapy Market Size by Type (2015-2020)6.4 North America Cancer Stem Cell Therapy Market Size by Application (2015-2020) 7 Europe7.1 Europe Cancer Stem Cell Therapy Market Size (2015-2020)7.2 Cancer Stem Cell Therapy Key Players in Europe (2019-2020)7.3 Europe Cancer Stem Cell Therapy Market Size by Type (2015-2020)7.4 Europe Cancer Stem Cell Therapy Market Size by Application (2015-2020) 8 China8.1 China Cancer Stem Cell Therapy Market Size (2015-2020)8.2 Cancer Stem Cell Therapy Key Players in China (2019-2020)8.3 China Cancer Stem Cell Therapy Market Size by Type (2015-2020)8.4 China Cancer Stem Cell Therapy Market Size by Application (2015-2020) 9 Japan9.1 Japan Cancer Stem Cell Therapy Market Size (2015-2020)9.2 Cancer Stem Cell Therapy Key Players in Japan (2019-2020)9.3 Japan Cancer Stem Cell Therapy Market Size by Type (2015-2020)9.4 Japan Cancer Stem Cell Therapy Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Cancer Stem Cell Therapy Market Size (2015-2020)10.2 Cancer Stem Cell Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Cancer Stem Cell Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Cancer Stem Cell Therapy Market Size by Application (2015-2020) 11 India11.1 India Cancer Stem Cell Therapy Market Size (2015-2020)11.2 Cancer Stem Cell Therapy Key Players in India (2019-2020)11.3 India Cancer Stem Cell Therapy Market Size by Type (2015-2020)11.4 India Cancer Stem Cell Therapy Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Cancer Stem Cell Therapy Market Size (2015-2020)12.2 Cancer Stem Cell Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Cancer Stem Cell Therapy Market Size by Type (2015-2020)12.4 Central & South America Cancer Stem Cell Therapy Market Size by Application (2015-2020) 13 Key Players Profiles13.1 AVIVA BioSciences13.1.1 AVIVA BioSciences Company Details13.1.2 AVIVA BioSciences Business Overview13.1.3 AVIVA BioSciences Cancer Stem Cell Therapy Introduction13.1.4 AVIVA BioSciences Revenue in Cancer Stem Cell Therapy Business (2015-2020))13.1.5 AVIVA BioSciences Recent Development13.2 AdnaGen13.2.1 AdnaGen Company Details13.2.2 AdnaGen Business Overview13.2.3 AdnaGen Cancer Stem Cell Therapy Introduction13.2.4 AdnaGen Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.2.5 AdnaGen Recent Development13.3 Advanced Cell Diagnostics13.3.1 Advanced Cell Diagnostics Company Details13.3.2 Advanced Cell Diagnostics Business Overview13.3.3 Advanced Cell Diagnostics Cancer Stem Cell Therapy Introduction13.3.4 Advanced Cell Diagnostics Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.3.5 Advanced Cell Diagnostics Recent Development13.4 Silicon Biosystems13.4.1 Silicon Biosystems Company Details13.4.2 Silicon Biosystems Business Overview13.4.3 Silicon Biosystems Cancer Stem Cell Therapy Introduction13.4.4 Silicon Biosystems Revenue in Cancer Stem Cell Therapy Business (2015-2020)13.4.5 Silicon Biosystems Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original here:

Latest Report on Cancer Stem Cell Therapy Market to Grow Significantly With Increasing Advancements in Technology, Says QYR - Owned

License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients

Preclinical Data Published in the Journal Nature Biotechnology Demonstrate Allogeneic CAR T Cells Overcome Immune Rejection and Exhibit Durable Tumor Eradication

SAN DIEGO, July 14, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company entered into an exclusive license agreement with Baylor College of Medicine covering alloimmune defense receptors, a first-in-class approach that renders off-the-shelf allogeneic cell products resistant to host immune rejection. Preclinical studies published in the journal Nature Biotechnology (https://www.nature.com/articles/s41587-020-0601-5) demonstrate that allogeneic cells engineered with a novel alloimmune defense receptor (ADR) are protected from both T- and NK-cell mediated rejection, and provide proof-of-concept that ADR-expressing allogeneic cell therapies can durably persist in immunocompetent recipients.

Allogeneic cell therapy requires a patient to endure systemic lympho-conditioning to suppress the immune system and mitigate cellular rejection, often resulting in severe blood cell deficiencies and related toxicities. There is great interest in strategies that enable allogeneic cells to overcome host immunity and evade immune rejection while maintaining a patients functional hematopoietic system, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. The published preclinical data provide compelling evidence that allogeneic cell therapies armed with novel alloimmune defense receptors can effectively abrogate both T- and NK-cell rejection responses and can persist and remain functional in immunocompetent patients.

ADRs are synthetic receptors that selectively recognize cell surface receptors, such as 4-1BB, that are uniquely expressed on activated lymphocytes, which are responsible for host immune rejection. The published preclinical findings show that the arming of allogeneic T cells with an ADR selectively eliminates alloreactive T and NK cells, while sparing resting lymphocytes. Importantly, in in vivo preclinical models of cancer, allogeneic T cells expressing both an ADR and a CD19-targeted chimeric antigen receptor (CAR) demonstrated increased expansion and persistence, resulting in sustained tumor eradication and a long-term survival benefit compared to conventional CD19-targeted CAR T cells.

There is tremendous promise for the use of off-the-shelf allogeneic cells as replacement therapy. One of the most significant barriers to overcome is host immunity, which can prevent the engraftment of allogeneic cells and the long-term replacement of a patients damaged or dysfunctional cells, said Maksim Mamonkin, Ph.D., Assistant Professor, Center for Cell and Gene Therapy, Baylor College of Medicine and the senior author on the Nature Biotechnology publication. We are excited for Fate Therapeutics to explore the use of alloimmune defense receptors in the development of rejection-resistant, iPSC-derived cellular therapies.

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Companys NK and T-cell product candidates and preclinical research and development programs, and the scope and enforceability of the Companys intellectual property portfolio. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of its product candidates may not be replicated in ongoing or future clinical trials or studies, the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and the risk that any of the patents owed or licensed by the Company may be challenged and that such a challenge may be successful, resulting in loss of any such patent or loss or reduction in the scope of one or more of the claims of a challenged patent. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

Read this article:

Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies -...

Biological, clinical and epidemiologic features of COVID-19

The comparison of features among COVID-19, SARS-CoV and MERS-CoV is summarized in Table1.

With high-throughput sequencing, researchers announced the sequencing of SARS-CoV-2. The genome of SARS-CoV-2 consists of 6 major ORFs that are common to coronaviruses, and the sequence of SARS-CoV-2 has almost 70% similarity to that of SARS-CoV and nearly 40% similarity to that of MERS-CoV [5, 6, 11, 12]. The main differences among SARS-CoV-2, SARS-CoV and MERS-CoV are in ORF1a and the sequence of gene spike coding protein-S [5], which was identified as a key protein that interacts with target cells.

In terms of electron microscopic morphology, SARS-CoV-2 virions are generally spherical, but some are polygonal. The diameter is between 60 and 140nm. The virus particles have prominent spines that are approximately 9 to 12nm, which cause the virus to have a coronal shape. According to the virus morphology observed under the microscope, the virus is consistent with other in the coronavirus family, including SARS-CoV and MERS-CoV [5, 13].

The receptor on the target cells is the factor determining how the virus enters the cell and which tissues are susceptible, and the spike protein initiates the merging of the viral envelope with the host cell cytomembrane. Existing experimental studies have shown that ACE2 is likely to be the cell receptor of SARS-CoV-2, and SARS-CoV-2 does not use other coronavirus receptors. The main receptors of SARS-CoV and MERS-CoV are ACE2 and hDPP4 (human dipeptidyl peptidase 4 or CD26), respectively [1, 5, 14].

Although the study of COVID-19 is still in progress, our summary and comparison of coronaviruses can be useful for further research and clinical applications. The clinical symptoms of COVID-19 are similar to those of SARS and MERS, including fever, cough, myalgia and fatigue. Almost all of the patients have pneumonia, and their chest CT examinations are abnormal [1, 4, 15,16,17]. However, those who are infected with SARS-CoV-2 rarely have significant upper respiratory signs and symptoms, including nosebleed, sneezing or sore throat, which indicates that the target cell may exist in the lower respiratory tract. This is consistent with the autopsy reports of patients with COVID-19 that show that SARS-CoV-2 infection mainly causes deep airway inflammatory reactions and alveolar damage. Some patients may also have headache, hemoptysis, diarrhea, dyspnea and lymphocytopenia, but patients are less likely to have gastrointestinal symptoms [4]. Complications include acute respiratory distress syndrome, acute heart injury, and secondary infections. COVID-19 patients can be divided into those with asymptomatic, mild and severe cases. For most patients, the incubation period of the virus is generally 714days. Typically, COVID-19 gradually progresses and worsens. Thus, each patients condition becomes more serious in the second week.

COVID-19, SARS, and MERS have different mortality rates. Among them, MERS had the highest fatality rate, and COVID-19 has the lowest fatality rate. It is worth noting that watery diarrhea is common in almost 60% of patients who suffer from SARS, and there is a typical biphasic clinical course [10, 18, 19]. In MERS, most patients have symptoms that include dry cough fever, malaise, myalgia, sore throat, headache, nausea, vomiting, and diarrhea, which are similar to the symptoms of SARS, but MERS has an unpredictable and erratic clinical course [19,20,21,22]. Fibrosis and consolidation in COVID-19 are less serious than the lesions caused by SARS, revealing that in COVID-19, the chest lesions are not primarily serous inflammation but rather are exudative reactions. Whether damage to the brain, myocardium, epicardium, kidneys, spleen and digestive organs is associated with viral infection needs further research.

Next-generation sequencing (NGS) and electron microscopy technology play critical roles in the early diagnosis of COVID-19, but their diagnostic values have been weakened by the use of specific nucleic acid detection technology [11, 23]. At present, clinically confirmed patients are usually diagnosed by collecting throat swabs and then detecting the nucleic acid of SARS-CoV-2.

Diagnosis based on clinical manifestations can be an early and rapid screening method. Patients with mild symptoms may not present positive signs. Patients in severe condition may have shortness of breath, moist rales in lungs, weakened breath sounds, dullness on percussion, and changes in voice, and the physical examination can help identify these symptoms. In addition, CT imaging plays an important role in the diagnosis. The imaging features of lesions show characteristic (1) distribution (mainly subpleural, along the bronchial vascular bundles); (2) quantity (often more than three lesions, occasionally single or double lesions); (3) shape (patchy, large block, nodular, lumpy, honeycomb-like or grid-like, cord-like, etc.); (4) density (mostly uneven, crazy-paving pattern mixed with ground glass opacity and interlobular septal thickening, consolidation and thickened bronchial wall, etc.); and (5) concomitant signs (e.g., air bronchogram, rare pleural effusion and mediastinal lymph node enlargement). However, these are not enough. COVID-19 needs to be distinguished from other known viruses that cause pneumonia, such as influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS-CoV, etc. and from Mycoplasma pneumonia, Chlamydia pneumonia, and bacterial pneumonia. In addition, COVID-19 should be distinguished from noninfectious diseases, such as vasculitis, dermatomyositis, and organizing pneumonia.

Research on identifying effective drugs has started, and there have been many in vitro and in vivo experiments being conducted [24]. Vaccines against SARS-CoV-2 are currently in development, and there are at least two kinds currently ready for testing. There are approximately 15 potential vaccine candidates in the pipeline globally using a wide range of approaches (such as messenger RNA, DNA, nanoparticle, and synthetic and modified virus-like particles). The vaccine candidates will be developed by a number of organizations using DNA, recombinant and mRNA vaccine platforms109. On 23 January 2020, The Coalition for Epidemic Preparedness Innovations (CEPI) announced that they will fund vaccine development programmes with Inovio, The University of Queensland and Moderna, Inc., with the target of testing the experimental vaccines clinically. It will likely take approximately a year for most candidates to enter phase 1 clinical trials except for those funded by CEPI. For SARS, the vaccines in development include viral vector-based vaccines, DNA vaccines, subunit vaccines, virus-like particle (VLP)-based vaccines, inactivated whole-virus (IWV) vaccines and live attenuated vaccines, and the latest findings for these vaccines are based on the review by Yong et al. (2019) in August 2019 [25]. There was one SARS vaccine trial conducted by the US National Institute of Allergy and Infectious Diseases. Both Phase I clinical trials reported positive results, but only one will proceed to the Phase 2 trial. For MERS, there is only one published clinical study on a vaccine developed by GeneOne Life Science & Inovio Pharmaceuticals [26]. For therapeutics, there are nine clinical trials registered with the clinical trials registry (ClinicalTrials.gov) investigating therapeutic agents for COVID-19. Five studies on hydroxychloroquine, lopinavir plus ritonavir and arbidol, mesenchymal stem cells, traditional Chinese medicine and glucocorticoid therapy usage have commenced recruitment, and the other four are on antivirals, interferon atomization, darunavir and cobicistat, Arbidol, and remdesivir [24].

COVID-19 patients admitted to a qualified hospital are given chemotherapy, including antiviral treatment, antibiotic therapy, corticosteroid therapy and other medications, such as ibuprofen as an antipyretic, nutrition support treatment, H2 receptor antagonists or proton pump inhibitors for gastrointestinal bleeding, and selective (M1, M3) receptor anticholinergic drugs for dyspnea, coughing, wheezing, and respiratory distress syndrome. Although -interferon atomization inhalation and oral lopinavir/ritonavir can be considered, the effectiveness of the combined use of antivirals is still unknown, given the lack of evidence from a randomized controlled trial (RCT). Given the high risk of adverse effects, there are limitations on the use of corticosteroids. Traditional Chinese medicine has shown a good effect with regard to both prevention and treatment. Fumigating rooms with moxa and wearing perfumed Chinese herb bags can help prevent community transmission. Huoxiang Zhengqi capsules are recommended for hypodynamia accompanied by gastrointestinal upset caused by COVID-19. For hypodynamia and fever, Jinhua Qinggan granules, Lianhua Qingwen capsules, Shufeng Jiedu capsules and Fangfeng Tongsheng pills are recommended [23].

Nursing care is important for isolated and critically ill patients, as classified according to the guidelines. Isolated patients at home should monitor their body temperature and breathing regularly. Patients are given oxygen therapy via a nasal catheter or a mask, antiviral drugs, antibacterial drugs, symptomatic treatments, nutritional support and psychological counselling. Critically ill patients are monitored with regard to their vital signs, water-electrolyte balance, acid-base balance, and the functioning of various organs. In addition to nutritional support and psychological counselling, they need oxygen therapy and some special treatments. For example, if a patient develops moderate to severe ARDS, invasive mechanical ventilation with the patient in a prone position needs to be initiated [23, 27].

According to Yang et al., the case fatality ratio (CFR) during the first weeks of the epidemic ranged from 0.15% (95% confidence interval [CI]: 0.120.18%) in mainland China excluding Hubei t 1.41% (95% CI: 1.381.45%) in Hubei Province excluding the city of Wuhan to 5.25% (95% CI: 4.985.51%) in Wuhan City based on data from the Wuhan Municipal Health Commission and the China and National Health Commission of China [28]. Chen et al. systematically described 99 cases of COVID-19 in Wuhan, China. Critically ill patients died of severe pneumonia, septic shock, respiratory failure and multiple organ failure (MOF). The authors reached a speculative conclusion that SARS-CoV-2 is more likely to infect older adult males with chronic comorbidities as a result of their weaker immune systems. In patients with severe coinfections, immune function is important in addition to the virulence of the pathogens. Old age, obesity, and the presence of comorbidities might be associated with increased mortality. In addition, a substantial decrease in the total number of lymphocytes indicates that SARS-CoV-2 consumes many immune cells and inhibits the bodys cellular immune function; therefore, a low absolute value of lymphocytes could be used as a reference index in the diagnosis of new SARS-CoV-2 infections in the clinic [29].

It is essential to analyze the infection source, transmission route, susceptible population and replication rate, especially the intermediate host and the exact route of transmission, to find the best measures to prevent the further spread of COVID-19.

The infection sources include patients, virus carriers, and infected animals that serve as viral reservoirs. Searching for the hosts of the virus, or for the infection sources, is a vital process in understanding the viral dynamics. SARS-CoV-2 has 96.2% genetic sequence similarity to the previously identified BatCoV RaTG13, suggesting that bats are most likely to be the host of SARS-CoV-2 [1, 3, 30, 31]. The cluster of cases in the seafood market was comprehensively analyzed, and sequence comparison revealed that pangolins are the most likely intermediate host for SARS-CoV-2 [30]. However, SARS-CoV and MERS-CoV were also identified as having zoonotic origins, and the animal reservoirs seemed to be bats [9, 32]. Although bat coronaviruses are genetically related, the intermediate hosts are involved in cross-species transmission, after which human-to-human transmission developed. In contrast to SARS-CoV-2, the intermediate host of SARS-CoV was mainly palm civets [9, 33, 34], and the intermediate host of MERS-CoV was thought to be dromedary camels [22, 35]. All three coronaviruses can be traced to bats, while there are different intermediate hosts involved in cross-species transmission. These three viruses have caused widespread epidemics that originated in animal reservoirs; the high morbidity and mortality levels have caused panic and substantial economic loss.

Viruses can directly infect people but can also infect one or more kinds of animals. Although these animals themselves do not cause disease, they can act as vectors for the virus and transmit it to humans; during this process, some viruses may mutate and evolve new characteristics. According to the experimental results of Peng et al. [5], SARS-CoV-2 can be transmitted through respiratory droplets and direct contact, confirming that while the main transmission route of SARS-CoV-2 is aerosols, other routes of transmission may exist. Moreover, a recent experiment conducted with recovering patients found that SARS-CoV-2 can also exist in the patients stool, suggesting that the fecal-oral route may be a route of transmisson [36]. Li et al. investigated cases of SARS and found that SARS was spread mainly by respiratory droplets [19]. By analyzing case data, Hui et al. also found that direct person-to-person transmission through close contact can also spread SARS-CoV [18]. MERS-CoV was mainly transmitted through close contact with infected family members or infected individuals in the hospital. Xiao et al. identified seven hypothesized transmission modes based on the three main transmission routes (long-range airborne, close contact, and fomite), and the infection risks associated with each hypothesis were estimated using the multiagent modeling framework. This showed that transmission occurred via both the long-range airborne and close contact routes [22]. Based on the available data, all three coronaviruses can be transmitted by breathing respiratory droplets that contain virions, which indicates that wearing masks is an effective means of protecting susceptible people. All three coronaviruses are transmitted from animals to humans and from humans to humans.

There is no evidence that people with certain characteristics are not susceptible to COVID-19. The available data suggest that people of all ages who have close contact with patients can be infected by SARS-CoV-2 [36,37,38]. The general public is susceptible, and the data are still being updated daily. The elderly population and patients with basic diseases are more susceptible to severe illness after infection, and children and infants can also be infected by SARS-CoV-2 [39]. SARS-CoV had a tendency to affect healthier and younger persons, with a mean patient age of 39.9years (range 191), and the male to female ratio was 11.3, with a slight female predominance. MERS-CoV had a tendency to affect the elderly and frail populations, especially males, with a mean age of 56years (range 1494), and the male to female ratio was 3.31 with a male predominance [8, 10, 40].

A commonly used measure of infectivity is the basic reproduction number (R0), which is the average number of people infected who pass the virus on to others without intervention. In other words, the value is equivalent to how many people can be infected by an average patient. The larger the R0 is, the harder it is to control the epidemic. Researchers have estimated the R0 to be in the range of 2.83.9, assuming extreme cases, which means that on average a COVID-19 patient passes the virus on to 2.83.9 healthy persons [28, 41]. In comparison, the R0 of MERS has been reported to be less than 1, and the R0 of SARS is estimated to be 3. Considering that the disease is now widespread around the world, the R0 of COVID-19 may change and could be higher than those of SARS and MERS.

As of May 24, 2020, there were caused 84536 confirmed cases of COVID-19, 4645 deaths and 79757 cured cases in China. A total of 5490640 cases have been diagnosed, and 346328 deaths have occurred worldwide. SARS infected more than 8098 people in 29 countries and caused 916 deaths, with a mortality rate of approximately 10%. MERS was first found in the Arabian Peninsula and infected approximately 2254 people (from 2012 through September 16, 2018) in 27 countries; MERS caused 800 deaths, with a mortality rate of approximately 35%. SARS was characterized by superspreading events, while COVID-19 is unique for its indiscriminate transmission among the general public. However, MERS seemed to be less aggressive [8, 10, 42].

Epidemiological changes have been monitored, taking into account potential routes of transmission and subclinical infections. The official platform updates the public daily on the number of newly diagnosed cases, deaths and cures in each administrative region based on data from the Centers for Disease Control and Prevention and hospitals at all levels. Since the outbreak, many emergency measures have been taken to reduce person-to-person transmission of SARS-CoV-2. For example, public services and facilities provide disinfectants on a routine basis to encourage appropriate hand hygiene, and physical contact with wet and contaminated objects is considered when dealing with the virus, especially fecal and urine samples that can potentially serve as an alternative route of transmission. China and other countries have implemented major prevention and control measures, including screening travelers, to control further spread of the virus [43]. There are many people donating money, vegetables, medical supplies, etc. to the areas affected by the epidemic. In Wuhan, two hospitals, Vulcan Mountain Hospital and Raytheon Mountain Hospital, were built within 10 days, which can contain 1000 and 1300 patients, respectively. According to the Peoples Daily, the National Health and Fitness Commission reported that there are more than 11000 critical care workers and more than 2000 intensive care unit nurses, and there will be more pooling of medical resources in places where they are most needed. The Chinese government has shut down schools and closed businesses to reduce transmission [44].

The outbreak has also caused widespread public concern. Husnayain et al. studied the potential to use Google Trends (GT) to monitor public restlessness regarding the COVID-19 epidemic, and they found that searches related to COVID-19 and face masks increased rapidly [45]. With the advent of 5G and the rapid development of the information age, it may be more convenient for the masses to obtain the latest news from the Internet; thus, Internet-based risk communication is becoming an appropriate strategy. There are many disease control organizations and medical institutions that have played an official role in this outbreak and provided accurate and reliable information to the public in a timely manner. For example, laboratory confirmation of COVID-19 was performed in five different institutions, namely, the China CDC, Chinese Academy of Medical Science, Wuhan Institute of Virology, and Academy of Military Medical Sciences, and Chinese Academy of Sciences [29]. According to the CCTV news, with scientific progress has enabled the use of advanced technologies to control this epidemic. In addition, the health code divides the public into three health situations, namely, green, red and yellow. This provides an effective method of facilitating crowd tracking and monitoring. Furthermore, the geographic information system (GIS), which has long been used by many health professionals when tracking and combating contagion, also plays an important role in the geographical tracking and mapping of epidemics. A range of practical online/mobile GIS and mapping dashboards and applications have come into use for tracking the COVID-19 epidemic [46].

Some treatments have been adopted in clinical practice, and a few have been successful [24, 47]. According to Prashant Pradhan, the first case cured in sevendays in the United States showed that the antiviral medication remdesivir may become one of the specific medicines for COVID-19; however, this remains to be verified through clinical trials [16]. According to the research by Wang, XF, et al. about the clinical manifestations and epidemiology in children with COVID-19 treated with lopinavir and ritonavir and without glucocorticoids and immunoglobulin, all 20 patients improved and were discharged from hospital. This may lead to the conclusion that childrens clinical symptoms of COVID-19 are nonspecific and milder than those in adults, which has significant clinical value [48].

Future research priorities may be focused on biological research on SARS-CoV-2 and clinical research on COVID-19 diagnosis and treatment. According to Pradhan et al., there are four unique insertions, which have similarity to HIV, in the S-protein in COVID-19, which may explain its contagiousness. The gene binding site may become a new target of therapeutics to prevent transmission of the virus [49]. Specifically, virus particles are found in the feces, which suggests that there may exist other routes of transmission, such as fecal-oral transmission. Previously, we focused on cutting off transmission routes mainly by limiting contact and preventing respiratory droplet transmission. This finding emphasizes the significance of dealing with the feces of the patient. Therefore, for patients who already have COVID-19, careful disposal of their feces is an important concern with regard to reducing viral transmission [36]. On the basis of the research by Hongzhou Lu, lopinavir/ritonavir, nucleoside analogs, neuraminidase inhibitors, remdesivir, peptide (EK1), Arbidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine and so on could be therapies for COVID-19, but the effects and safety remain to be tested in clinical trials [27].

3D structures of remdesivir, chloroquine, ciclesonide, niclosamide, and lopinavirus were obtained from NCBI PubChem. The crystal structure of ACE2 (PDB code: 6M17) was obtained from the Protein Data Bank. The ligands within the crystal structure complex were extracted by PyMOL software (San Carlos, CA, USA). AutoDock 4.2 was used for the docking system test. AutoDock tools initialized the ligands by adding gasteiger charges, merging nonpolar hydrogen bonds, and setting rotatable bonds. The ligands were rewritten into PDBQT format, which can be read by Autodock software (AutoDock 4.2, San Carlos, CA, USA). AutoDock Tools were used to add polar hydrogen to the entire receptor. The grid box was set to contain the entire receptor region. The receptor output was also saved in PDBQT format. AutoDock Vina was set with the macromolecule held fixed and the ligands flexible. Affinity maps for all the atom types present, as well as an electrostatic map, were computed, with a grid spacing of 0.375. The structural models were collected from the lowest-energy docking solution of each cluster of autodocks. It is evident from the findings of Fig.2 and Table2 that combinations of antiviral agents are more successful than a single drug.

AutoDock calculations were performed to determine and compare the binding affinities of remdesivir, chloroquine, ciclesonide, niclosamide, and lopinavirus to ACE2. LEU: Leucine, PHE: Phenylalanine, MET: Methionine, VAL: Valine), ILE: Isoleucine, TRP: Ttryptophan, TYR: Tyrosine

The outbreak of SARS renewed interest in this family of viruses and resulted in the development of new drugs, among which remdesivir, chloroquine, ciclesonide, niclosamide, and lopinavirus are the most promising [50,51,52]. In addition, as mentioned above, ACE2 plays a vital role in the development of COVID-19 [53]. With regard to testing the effectiveness of previous medicines used by scientists for the treatment of diseases caused by coronaviruses, AutoDock calculations have been performed to classify specific binding amino acids and thus to determine the likely common cure targets for ACE2. As shown in Table2 and Fig.2, we found that chloroquine and ciclesonide share similar binding amino acid residues (MET124, LEU127, ILE472 and VAL589). Likewise, remdesivir and niclosamide also possess MET124. Taken together, we might therefore hypothesize that MET124 plays a key role in the efficiency of these drugs targeting ACE2. MET24 appears to be a potential target for COVID-19. However, there is no similar amino acid for lopinavir, suggesting that further studies are needed to elucidate the molecular mechanism of lopinavir treatment of COVID-19.

Read more:

Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2 - Infectious Diseases of Poverty - BioMed...